Products
Eftrenonacog alfa was approved in the United States in 2014 and in the EU and many countries in 2016 as a powder and solvent for solution for injection (Alprolix).
Structure and properties
Eftrenonacog alfa is a recombinant fusion protein consisting of human coagulation factor IX covalently linked to the Fc fragment of human immunoglobulin IgG1 (abbreviation “rFIXFc”). Eftrenonacog alfa is produced by biotechnological methods.
Effects
Eftrenonacog alfa (ATC B02BD04) replaces the missing factor IX, which plays a central role in blood clotting. As a result, bleeding can be prevented. The combination with the Fc fragment results in a long half-life of 82 hours. The Fc fragment interacts with the neonatal Fc receptor.
Indications
For the prevention and treatment of bleeding in pretreated patients with hemophilia B (congenital factor IX deficiency).
Dosage
According to the SmPC. The drug is administered as an intravenous injection.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Drug-drug interactions are not known.
Adverse effects
The most common possible adverse effects include headache, oral paresthesia, and obstructive uropathy.
